The compounds returning to legal compounding status have decades of preclinical research and growing clinical evidence
If the liquid looks cloudy, contains visible particles, or has changed color, do not use it
Its entire evidence base is preclinical rodent work much of it from the lab that created the compound and there is a notable mismatch between how those studies dosed it (oral and peripheral) and how community sources describe taking it (subcutaneous and intranasal)
Reconstitution: 3.0 mL bacteriostatic water per 100 mg GHK-Cu vial gives ~33.3 mg/mL for accurate unit measurements
It pairs well with MOTS-c, CJC-1295/Ipamorelin, GLP-1s, tesamorelin, and AOD-9604 when monitored properly
Furthermore, this studys robust design is not without limitations